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The 42nd Annual Symposium on the Biology of the
Skin, entitled ‘‘The Genetics of Skin Disease’’, was held
in SnowmassVillage, Colorado, in July 1993.That meet-
ing presented the opportunity to discuss how modern
approaches to molecular genetics and molecular biol-
ogy could be applied to understanding the mechanisms
of skin diseases. The published proceedings of this
meeting stated that ‘‘It is an opportune time to examine
the genetics of skin disease’’ (Norris et al, 1994). Indeed,
this meeting just caught the wave of early pioneering
studies that have helped us to understand the molecular
basis of a large number of genodermatoses. This over-
view presented in the 50th Annual Symposium on the
biology of the skin, highlights the progress made in
the molecular genetics of heritable skin diseases over
the past decade. Key words: Genodermatoses/epidermolysis
bullosa/pseudoxanthoma elasticum JID Symposium Proceed-
ings 7:6 ^16, 2002
T
he recent progress made in molecular genetics of
heritable skin diseases is abundantly evident from
the present vantage point, as reviewed in the 50th
Annual Montagna Symposium on the Biology of
Skin, also held in Snowmass Village, Colorado, in
July 2001. At the time of our previous meeting, almost a decade
ago, the molecular basis of the prototypic genodermatoses, such
as epidermolysis bullosa (EB), was beginning to emerge as the
¢rst mutations in the keratin 5 and 14 genes in the simplex forms
and in the type VII collagen gene in the dystrophic variants
had just appeared in the literature (Epstein, 1992; Fuchs, 1992;
Christiano et al, 1993; Hilal et al, 1993). At the same time, there
was very little understanding of the molecular basis of complex
multisystem disorders, such as pseudoxanthoma elasticum (PXE),
the Ehlers^Danlos syndrome, and the Marfan syndrome. Over
the ensuing years, this situation has very quickly changed, and
there has been tremendous progress towards understanding the
molecular basis of di¡erent forms of single-gene heritable disor-
ders. In fact, mutations have now been identi¢ed in more than
200 distinct genes in a manner that the genetic lesions explain
the spectrum of phenotypic manifestations encountered in these
diseases (Table I, Pulkkinen et al, 2002a).
PREDICTABLE AND SURPRISING CANDIDATE GENES
Examination of the mutation database in these diseases has
revealed a number of genes that could have been predicted, on
the basis of clinical, histopathologic, immunohistochemical, and/
or ultrastructural analysis, to serve as candidate gene/protein sys-
tems. For example, in the case of EB, we initially postulated that
mutations in the structural genes expressed within the cutaneous
basement membrane zone (BMZ) could harbor mutations that
explain the fragility of the skin at the dermal^epidermal junction
(Uitto and Christiano, 1992).This postulate has now been veri¢ed
by demonstration of a large number of distinct mutations in as
many as 10 di¡erent genes expressed within the cutaneous BMZ
(see below). At the same time, a number of mutated genes have
turned out to be rather surprising, and the exact relationship of
the mutations in the a¡ected genes and their consequences at the
clinical and morphologic level are not well understood. An ex-
ample of such conditions is PXE, in which we and others have
recently demonstrated mutations in the ABCC6 gene encoding
the MRP6 protein, a putative ATP-dependent transmembrane
pump of unknown function (Bergen et al, 2000; Le Saux et al,
2000; Ringpfeil et al, 2000; Struk et al, 2000). Surprisingly, this
gene is expressed primarily, if not exclusively, in the liver and
the kidneys, and the pathomechanistic links between the under-
lying genetic mutations in ABCC6 and calci¢cation of pleio-
morphic elastic structures in the skin, the eyes, and the arterial
blood vessels remain unclear.
To illustrate the progress made in understanding the genetic
basis of heritable skin diseases in general, we will highlight
two speci¢c disease entities, in which we have been major con-
tributors, namely epidermolysis bullosa and pseudoxanthoma
elasticum.
THE PARADIGM OF EB
An example of the conditions in which spectacular success has
recently been made is EB, a heterogeneous group of mechano-
bullous disorders manifesting with blistering and erosions of the
skin (Sybert, 1997; Fine et al, 2000; Bruckner-Tuderman, 2002).
The extent of skin involvement, combined with a number of
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Table I. Genodermatoses with known gene defects
Diseasea Mutated geneb A¡ected protein/function Referencec
Epidermal fragility disorders
Dystrophic EBd COL7A1 TypeVII collagen Pulkkinen and Uitto (1999)
Junctional EB LAMA3, LAMB3, a3, b3, and g2 chains of laminin 5, Pulkkinen and Uitto (1999)
LAMC2, COL17A1 Type XVII collagen
EB with pyloric atresia ITGA6, ITGB4 a6b4 integrin Pulkkinen and Uitto (1999)
EB with muscular dystrophy PLEC1 Plectin Pulkkinen and Uitto (1999)
EB simplex ogna PLEC1 Plectin Koss-Harnes et al (2002)
EB simplex KRT5, KRT14 Keratins 5 and 14 Irvine and McLean (1999)
Ectodermal dysplasia with skin
fragility
PKP1 Plakophilin McGrath (1999)
Hailey^Hailey disease ATP2C1 ATP-dependent calcium transporter Hu et al (2000)
Keratinization disorders
Epidermolytic hyperkeratosis KRT1, KRT10 Keratins 1 and 10 Irvine and McLean (1999)
Ichthyosis hystrix KRT1 Keratin 1 Sprecher et al (2001a)
Epidermolytic PPK KRT9 Keratin 9 Irvine and McLean (1999)
Non-epidermolytic PPK KRT1, KRT16 Keratins 1 and 16 Irvine and McLean (1999)
Ichthyosis bullosa Siemens KRT2e Keratin 2e Irvine and McLean (1999)
Pachyonychia congenita, types 1 and 2 KRT6a, KRT6b, Keratins 6a, 6b, 16 and 17 Irvine and McLean (1999)
KRT16, KRT17
White sponge naevus KRT4, KRT13 Keratins 4 and 13 Irvine and McLean (1999)
X-linked recessive ichthyosis STS Steroid sulfatase Bonifas et al (1987)
Lamellar ichthyosis TGM1 Transglutaminase 1 Ishida-Yamamoto and Iizuka (1998)
Mutilating keratoderma with
ichthyosis
LOR Loricrin Maestrini et al (1996)
Non-bullous congenital
ichthyosiform
ALOXE3 Lipoxygenase-3 Jobard et al (2002)
erythroderma (NCIE) ALOX12B 12(R)-lipoxygenase
Vohwinkel’s syndrome GJB2 Connexin 26 Maestrini et al (1999)
PPKwith deafness GJB2 Connexin 26 Richard (2001)
Erythrokeratodermia variabilis GJB3, GJB4 Connexins 31 and 30.3 Richard (2001)
Darier disease ATP2A2 ATP-dependent calcium transporter Sakuntabhai et al (1999)
Striate PPK DSP, DSG1 Desmoplakin, desmoglein 1 Armstrong et al (1999); Rickman et al
(1999)
Conradi^Hˇnermann^Happle
syndrome
EBP Delta 8-delta 7 sterol isomerase (emopamil
binding protein)
Derry et al (1999)
Mal de Meleda ARS SLURP-1 (secreted Ly-6/uPAR related
protein 1)
Fischer et al (2001)
Chanarin^Dorfman syndrome CGI 58 Member of esterase/lipase/thioesterase
subfamily
Lefevre et al (2001)
Hair disorders
Woolly hair, keratoderma and
cardiomyopathy (Naxos disease)
DSP, PG Desmoplakin, plakoglobin Norgett et al (2000); McKoy et al
(2000)
Generalized atrichia with papular
lesions
VDR Vitamin D receptor Zhu et al (1998)
Congenital atrichia HR Hairless (a transcription factor) Ahmad et al (1999)
Monilethrix HHB1, hHB6 Hair cortex keratins 1 and 6 Korge et al (1998);Winter et al (1997)
Familial cylindromatosis CYLD1 Tumor-suppressor protein Bignell et al (2000)
Pigmentation disorders
Albinism (di¡erent forms) TYR Tyrosinase Boissy and Nordlund (1997)
p Putative membrane transporter protein Boissy and Nordlund (1997)
OA1 Member of G protein-coupled receptors Boissy and Nordlund (1997)
TRP1 Tyrosinase-related protein Boissy and Nordlund (1997)
OCA4 MATP, a membrane-associated transporter
protein
Newton et al (2001)
Chediak^Higashi syndrome CHS1 Lysosomal tra⁄cking regulator Nagle et al (1996)
Hermansky^Pudlak syndrome HPS1 Putative transmembrane protein with
unknown function
Boissy and Nordlund (1997)
ADTB3A Coat protein involved in vesicle formation
HPS3 Protein with unknown function Anikster et al (2001)
HPS4 Protein with unknown function Suzuki et al (2002)
Piebaldism KIT Proto-oncogene, a transmembrane tyrosine Giebel and Spritz (1991)
kinase receptor for stem cell factor
Tietz syndrome MITF Microphthalmia-associated transcription
factor
Nordlund et al (1998)
Waardenburg syndrome PAX3, MITF Transcription factors Nordlund et al (1998)
Phenylketonuria PAH Phenylalanine hydroxylase DiLella et al 1986
Richner-Hanbart syndrome TAT Tyrosine aminotransferase Natt et al., 1992
HERITABLE SKIN DISEASES 7VOL. 7, NO. 1 DECEMBER 2002
Diseasea Mutated geneb A¡ected protein/function Referencec
Porphyrias
Congenital erythropoietic porphyria UROS Uroporphyrinogen III synthase Sassa and Kappas (2000)
Erythropoietic protoporphyria FECH Ferrochelatase Sassa and Kappas (2000)
Familial porphyria cutanea tarda URO-D Uroporphyrinogen decarboxylase Sassa and Kappas (2000)
Variegate porphyria PPO Protoporphyrinogen oxidase Sassa and Kappas (2000)
Coproporphyria CPO Coproporphyrinogen oxidase Sassa and Kappas (2000)
Multisystem disorders
Gingival ¢bromatosis type I SOS1 Guanine nucleotide exchange factor Hart et al (2002)
Hypotrichosis with juvenile macular
dystrophy
CDH3 P-cadherin Sprecher et al (2001b)
Trichothiodystrophy XPB, XPD Complementation groups B and D Berneburg and Lehmann (2001)
Tricho-rhino^phalangeal syndrome
type I
TRPSI Zinc ¢nger protein Momeni et al (2000)
Giant axonal neuropathy GAN Gigaxonin Bomont et al (2000)
Cockayne syndrome CSA/CKN1, CSB Transcription-repair coupling factors Nakura et al (2000)
Human nude/SCID WHN Winged-helix transcription factor Frank et al (1999)
Fabry’s disease GLA Alpha-galactosidase A Peters et al (1997)
Ataxia telangiectasia ATM Protein kinase Spacey et al (2000)
Hereditary hemorrhagic
telangiectasia
ENG, Endoglin Azuma (2000)
ALK-1 Activin receptor-like kinase I
Papillon^LefeŁ vre syndrome CTSC Cathepsin C Toomes et al (1999); Nakano et al
(2001c)
Haim^Munk syndrome CTSC Cathepsin C Hart et al (2000)
Dyskeratosis congenita, X-linked,
autosomal dominant
DKC1 Dyskerin Marciniak et al (2000)
hTR RNA component of telomerase Vulliamy et al (2001)
Netherton syndrome SPINK5 LEKTI (lympho-epthelial Kazal-type
inhibitor)
Chavanas et al (2000)
Lipoid proteinosis ECM1 Extracellular matrix protein 1 Hamada et al (2002)
Multiple cutaneous and uterine
leiomyomatosis
FH Fumarate hydratase Tomlinson et al (2002)
Sj˛gren^Larsson syndrome FALDH Fatty aldehyde dehydrogenase Rizzo (1998)
Refsum disease PHYH Phytanoyl-CoA hydroxylase Gould and Valle (2000)
Hyperkeratotic cutaneous capillary-
venous malformation
CCM1 KRIT1 (KREV1 interacting protein) Eerola et al (2000)
Milroy’s disease VEGFR-3 Vascular endothelial growth factor
receptor
Irrthum et al (2000)
Glomuvenous malformations VMBLOM Glomulin Brouillard et al (2002)
Waardenburg^Hirschsprung
syndrome
EDN3 Endothelin-3 Edery et al (1996)
EDNRB Endothelin receptor B Attie et al (1995)
SOX10 Transcription factor Pingault et al (1998)
Cutis laxa ELN, FBLN5 Elastin, Fibulin 5 Uitto and Pulkkinen (2002); Loeys et al,
2002
Williams syndrome ELN Contiguous gene deletion syndrome,
including elastin
Uitto and Pulkkinen (2002)
Marfan syndrome FBN1 Fibrillin 1 Le Parc et al (2000)
Pseudoxanthoma elasticum ABCC6 MRP6, a multidrug resistance associated
protein
Uitto et al (2001)
Ehlers^Danlos syndrome COL1A1, COL1A2, Type I, III and V collagens, procollagen Steinmann et al (2002); Mao and
Bristow (2001);(di¡erent variants) COL3A1, COL5A1, N-peptidase, procollagen-lysine 2-
oxoglutarate 5-dioxygenase (lysyl
hydroxylase), xylosylprotein 4-beta-
galactosyl-transferase, tenascin-X
Okajima et al (1999); Schalkwijk et al
(2001)
COL5A2,
ADAMTS2,
PLOD, B4GALT7,
TNX
Progressive osseous heteroplasia
(POH)
GNAS1 Gsa, an a-subunit of the stimulatory G
protein
Shore et al (2002)
Menkes’ syndrome ATP7A ATP-dependent copper transporter Kaler (1998)
Occipital horn syndrome ATP7A ATP-dependent copper transporter Kaler (1998)
Werner syndrome WRN DNA helicase Nakura et al (2000)
Bloom syndrome BLM DNA helicase Nakura et al (2000)
Rothmund^Thomson syndrome RECQ4 DNA helicase Nakura et al (2000)
Neuro¢bromatosis NF1, NF2 Neuro¢bromins 1 and 2 MacCollin and Kwiatkowski (2001)
Tuberous sclerosis TSC1,TSC2 Hamartins 1 and 2 MacCollin and Kwiatkowski (2001)
Griscelli syndrome RAB27A, MYO5A Ras-associated protein, MyosinVa Menasche et al (2000); Pastural et al
(2000)
Wiskott^Aldrich syndrome WAS WASP (Arp2/3 complex interacting
protein)
Nonoyama and Ochs (1998)
Table I. Continued.
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extracutaneous manifestations encountered in di¡erent variants
of EB, can cause considerable morbidity and, in some cases, pre-
mature demise of the a¡ected individuals. EB has been tradition-
ally divided into three broad categories based on the level
of tissue separation within the cutaneous BMZ: the simplex,
junctional, and dystrophic types (Fine et al, 2000). More recently,
we have proposed an additional subgroup, the hemidesmosomal
variants of EB, which include generalized atrophic benign EB,
EB with pyloric atresia, and EB with muscular dystrophy (Pulk-
kinen and Uitto, 1998; Table II). As of today, mutations have
Diseasea Mutated geneb A¡ected protein/function Referencec
Ectrodactyly, ectodermal dysplasia,
and cleft lip/palate syndrome 3
(EEC3)
TP63 Tumor protein p63 Celli et al (1999)
Hay^Wells syndrome (AEC) TP63 Tumor protein p63 McGrath et al (2001)
Hyperammonemia with reduced
ornithine, citrulline, arginine, and
proline
P5CS Delta(1)-pyrroline-5-carboxylate synthase Baumgartner et al (2000)
Hereditary angiodema C1NH C1 esterase inhibitor Bowen et al (2001)
Hidrotic ectodermal dysplasia GJB6 Connexin 30 Lamartine et al (2000)
Anhidrotic ectodermal dysplasia,
X-linked
ED1 Ectodysplacin A Kere et al (1996)
autosomal recessive and dominant DL Ectodysplacin A receptor Monreal et al (1999)
X-linked anhidrotic ectodermal
dysplasia with immunode¢ciency
(EDA-ID), osteopetrosis and
lymphedema (OL-EDA-ID)
IKBKG NEMO (modulator of NF-kappaB
signaling)
Do⁄nger et al (2001)
Incontinentia pigmenti IKBKG NEMO (modulator of NF-kappaB
signaling)
Berlin et al (2002); Smahi et al (2000)
Cartilage-hair hypoplasia RMRP Endoribonuclease RNase MRP RidanpQQ et al (2001)
Bruton agammaglobulinemia BTK BPK, tyrosine kinase Jones and Gaspar (2000)
Hyper^IgM syndrome TNSF5 CD40 ligand, a member of tumor necrosis
factors
Jones and Gaspar (2000)
Chronic granulomatous disorder CYBA P22 phox, a-subunit of cytochrome b Jones and Gaspar (2000)
CYBB Gp91 phox, b-subunit of cytochrome b
NCF1 Neutrophil cytosol factor-1
NCF2 Neutrophil cytosol factor-2
Blau syndrome CARD15/NOD2 Member of the family of apoptosis
regulators
Miceli-Richard et al (2001)
Carney complex PRKAR1A Protein kinase A regulatory subunit 1a Kirschner et al (2000)
Muckle^Wells syndrome CIAS1 Angiotensin/vasopressin receptor AII/Avp Dode et al (2002)
Familial cold urticaria CIAS1 Angiotensin/vasopressin receptor AII/Avp Dode et al (2002)
Acrodermatitis enteropathica SLC39A4 hZIP4, a zink transporter protein Kˇry et al (2002)
Multiple-Lentigines/LEOPARD
syndrome
PTPN11 Protein-tyrosine phosphatase, nonreceptor-
type, 11
Digilio et al (2002)
Homocystinuria CBS Cysiathione b-synthetase Kruger et al, 1995
Hunter’s syndrome IDS Iduronate 2-sulfatase Wilson et al, 1990
Hurler’s syndrome IDUA a-urodinase Scott et al, 1995
Nail-Patella syndrome LMX1B Homeobox domain transcription factor Morello et al, 2001
MEN 1 MEN1 Menin, Jun D binding protein Bassett et al, 1998
Tangier disease CERP Cholesterol e¥ux regulatory protein Brooks-wilson et al, 1999
Alkaptonuria HGD Homogentisic acid oxidase Fernandez-Canon et al, 1996
Familial Mediterranean fever MEFV Marenstrin, PMN inhibitor International FMF Consortium, 1997
Farber’s disease ASAH Acid ceramidase Koch et al, 1996
Gaucher’s disease GBA b-glucocerebrosidase Tsuji et al, 1987
Cancer disorders
Cowden syndrome PTEN Phosphatase and tensin homolog Bonneau and Longy (2000)
Bannayan^Zonan syndrome PTEN Phosphatase and tensin homolog Bonneau and Longy (2000)
Basal cell nevus syndrome PTC Patched (drosophila homolog) Bale et al (1998); Ingham et al (1998)
Hereditary melanoma CDK4 Cyclin-dependent kinase 4 Platz et al (2000)
CDKN2A Cyclin-dependent kinase inhibitor 2a
Muir^Torre syndrome MSH2 Mismatch repair protein Dore et al (1999)
Peutz^Jeghers syndrome STK11/LKB1 Protein kinase Rowan et al (1999); Dong et al (1998)
Xeroderma pigmentosum XPA, XPB, XPC, Complementation groups A-G Berneburg and Lehmann (2001)
DNA polymerase
(di¡erent complementation groups)
XPD, XPE, XPF, Z (eta)
XPG, hRAD30
aEB, epidermolysis bullosa; PPK, palmoplantar keratoderma.
bFor details of the genes, see Online Mendelian Inheritance in Man (OMIM) database, www.ncbi-mim.nih.gov/Omim/, or the corresponding references.
cIf a recent, comprehensive review on the molecular genetics of the corresponding disease exists, the reference is included. In other cases, pertinent original publications
are referenced.
dFor details on EB, seeTable II and the text.
(Modi¢ed from Pulkkinen et al, 2002a.)
Table I. Continued.
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been identi¢ed in 10 distinct genes expressed at the cutaneous
BMZ in di¡erent variants of EB (Pulkkinen and Uitto, 1999).
Examination of the mutation database suggests that the types
and combinations of the mutations, their positions along the
a¡ected proteins, and the dynamic interplay of the mutant
alleles on the individuals’ genetic background will determine the
continuum of severity in the spectrum of clinical manifestations
of EB.
Particularly instructive regarding the progress made in under-
standing the molecular basis of di¡erent variants of EB and in
explaining the clinical spectrum of the disease are the dystrophic
forms of EB (DEB).There is considerable genetic and phenotypic
variability in DEB. First, the DEB can be inherited in either an
autosomal dominant or autosomal recessive fashion. Second, the
clinical severity is highly variable demonstrating a spectrum of
manifestations. For example, the most severe form of DEB, the
Hallopeau^Siemens type, manifests with mutilating scarring
with joint contractures, corneal erosions, esophageal strictures,
and propensity to formation of cutaneous squamous cell carcino-
mas that can lead to premature demise of the a¡ected individuals
(Fine et al, 2000). A clinically milder form, the mitis variant of
recessive DEB, is characterized by life-long blistering tendency,
with limited scarring and less frequent extracutaneous manifesta-
tions. In fact, in some cases the clinical severity of mitis recessive
DEB can manifest only with subtle nail changes and occasional
blistering.
In general, patients with dominantly inherited forms of DEB
tend to have a relatively mild phenotype, and they often show
blistering only on the hands and feet, and occasionally there is
only minimal cutaneous involvement with nail dystrophy. Thus,
the dominantly inherited DEB can be indistinguishable from the
mitis recessive DEB on clinical, immunohistochemical, and ul-
trastructural grounds. Speci¢cally, besides the mild clinical fea-
tures, immunohistochemistry is positive, although occasionally
attenuated, for type VII collagen epitopes, and diagnostic trans-
mission electron microscopy usually reveals the presence of some
anchoring ¢brils which, however, can be either reduced in num-
ber or morphologically altered in both forms of DEB.This situa-
tion then poses a diagnostic dilemma concerning the mode of
inheritance, de novo dominant vs mitis recessive DEB (Hashimoto
et al, 1999). As discussed below, this dilemma can be resolved by
DNA analysis of the mutations in the type VII collagen gene
(COL7A1).
Distinct mutations have been disclosed in COL7A1 both in
DDEB and RDEB in a large number of families (Table II). A
characteristic genetic lesion in the most severe recessive DEB is
premature termination codon-causing mutation, resulting either
from a nonsense mutation or from small out-of-frame insertions
or deletions or splicing mutations in both COL7A1 alleles. These
mutations are distributed along the entire type VII collagen mo-
lecule, and most of them are family speci¢c, only a few of them
being recurrent (Fig 1). A characteristic genetic lesion in domi-
nantly inherited forms of DEB is a glycine substitution mutation
in one allele of COL7A1 residing within the collagenous domain
of the proa1(VII) chain (Fig 1). The mutated polypeptides are
full-length and capable of assembling into triple-helical collagen
molecules in combination with wild-type polypeptides (Uitto
and Pulkkinen, 2001); however, the presence of the glycine sub-
stitution destabilizes the collagenous triple-helix, and the pre-
sence of the mutated polypeptides causes a dominantly inherited
disease through dominant negative interference. Thus, analysis of
the type of mutations and their combinations along the type VII
collagen gene provides an explanation for the di¡erent modes of
inheritance (dominant versus recessive) and the severity of the dis-
ease, even though the mutations reside in the same gene
(COL7A1) (Pulkkinen and Uitto, 1999).
THE GENETIC BASIS OF PXE
Another example of a condition in which recent progress has
provided understanding of the molecular basis of a genodermatosis
is PXE, a systemic heritable connective tissue disorder character-
ized by progressive calci¢cation of elastic structures in the skin,
the eyes, and the cardiovascular system. Certain clinical features,
including delayed onset of the clinical manifestations and consid-
erable intra- and interfamilial phenotypic variability, have been
puzzling (Neldner, 1988). Adding to the complexity of PXE is
Table II. Molecular heterogeneity of epidermolysis bullosa
Variant of EBa Cleavage plane Mutated genes/polypeptides Chromosomal
Locus
A¡ected protein systems/interactions
Simplex Basal keratinocytes KRT5/Keratin 5 (K5) 12q13 Keratins 5 and 14, the major components of
intermediate ¢laments expressed in basal cellsKRT14/Keratin 14 (K14) 17q12-q21
Hemidesmosomal Hemidesmosome^
lamina lucida
interface
EB-MD PLEC1/Plectin 8q24 Plectin, located in the inner plaque of
hemidesmosomes, interacts with intermediate
¢laments providing integrity to the basal
keratinocytes
EB-PA ITGA6/a6 integrin 2q24-q31 The subunit components of a6b4 integrin, a
transmembrane complex extending from the outer
plaque of hemidesmosomes to the lamina lucida
ITGB4/b4 integrin 17q25
GABEB COL17A1/a1 chain of type XVII
collagen (BPAG2/the 180-kD
bullous pemphigoid antigen
10q24.3 Type XVII collagen/the 180-kD bullous
pemphigoid antigen, a transmembrane component
of anchoring ¢laments, traverses lamina lucida
providing integrity to the basement membrane
zone
Junctional Lamina lucida LAMA3/laminin a3-chain 18q11.2 The a3-, b3-, and g2-chains are subunit
polypeptides of laminin 5, located in the lamina
densa/lamina lucida interface, interacts with a6b4
integrin and typeVII collagen
LAMB3/laminin b3 chain 1q32
LAMC2/laminin g2-chain 1q25-q31
Dystrophic Papillary dermis COL7A1/a1 chain of type VII
collagen
3p21.1 TypeVII collagen is a major component of
anchoring ¢brils extending from lamina densa to
the papillary dermis
aEB, epidermolysis bullosa; EB-MD, EB with muscular dystrophy; EB-PA, EB with pyloric atresia; GABEB, generalized atrophic benign EB.
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the fact that both autosomal recessive and autosomal dominant
inheritance patterns have been reported, and in many cases PXE
is sporadic without family history, the precise mode of inheri-
tance thus being unclear (Pope, 1975). Furthermore, the genetic
complexity has been compounded by suggestions that obligate
heterozygous carriers in families with autosomal recessive forms
of PXE may show minimal manifestations of the disease
(Bacchelli et al, 1999; Sherer et al, 2001). Nevertheless, the involve-
ment of the elastic structures in the skin, the eyes, and the cardi-
ovascular system, and the accumulation of a number of
extracellular matrix components, including ¢bronectin and
vitronectin as well as various proteoglycan/glycosaminoglycan
complexes, in the lesional areas of skin in association with elastic
¢bers, have suggested that PXE is a primary heritable connective
tissue disease. In fact, it has been considered as a prototype of
such conditions with the primary involvement of elastic ¢bers
(McKusick, 1972).
The underlying molecular defect in PXE has remained un-
known until recently. Initial observations indicating pathology
in the elastic ¢bers suggested that elastin and elastin-associated
micro¢brillar proteins could serve as candidate gene/protein sys-
tems in PXE. Subsequently, however, the genes encoding elastin
as well as elastin-associated proteins, such as ¢brillins 1 and 2 and
lysyl oxidase on chromosomes 15 and 5, were excluded by genetic
linkage analysis. Subsequent positional cloning approaches al-
lowed mapping of the PXE gene to the short arm of chromo-
some 16, and the critical interval was further narrowed to B500
kb within the chromosomal region 16p13.1 (Le Saux et al, 1999;
Cai et al, 2000). Examination of the genome database revealed
that this region contained four distinct genes with no apparent
relation to the extracellular matrix of connective tissue in general
or the elastic ¢ber system in particular.Two of the genes, ABCC1
and ABCC6, encode proteins, MRP1 and MRP6, respectively,
that are members of the multiple drug resistance-associated pro-
tein (MRP) family. Another gene, NPIP, was found to encode
the nuclear pore interacting protein, whereas the fourth gene,
pM5, encodes a protein with unknown function but shares some
similarity with the conserved domain within the collagenase
family of proteins.
Sequencing of the four candidate genes within the critical
PXE interval resulted in identi¢cation of pathogenetic mutations
in the ABCC6 gene, which encodes MRP6, a member of the
ATP-dependent membrane transporter family of proteins (Le
Saux et al, 2000; Ringpfeil et al, 2000). Sequence information
derived from full-length ABCC6 cDNA predicts that MRP6
has three transmembrane spanning domains and two intracellular
nucleotide-binding folds (NBF1 and NBF2) (Fig 2). The NBF
domains contain conservedWalker motifs, critical for ATP bind-
ing and for the function of the protein as a transmembrane trans-
porter. Mutation detection strategies have identi¢ed a number of
single-base pair substitutions, resulting in missense or nonsense
mutations, as well as several small insertions and deletions or
Figure1. Illustration of the molecular heterogeneity in the dystrophic forms of EB. The structural organization of the type VII collagen a1(VII)
polypeptide deduced from the primary nucleotide sequence of full-length cDNA. The polypeptide consists of a collagenous domain that is £anked by N-
and C-terminal noncollagenous domains with modular structures, as indicated on the lower left corner. The arrows indicate positions of distinct mutations
disclosed in families with dystrophic forms of EB. The mutations depicted above the a1(VII) collagen polypeptide are recessive, and most of them cause
premature termination codons, either as a result of nonsense mutations, insertions, or deletions, or as out-of-frame exon skipping mutations, predicting
synthesis of a truncated polypeptide or downregulation of the corresponding mRNA transcript through nonsense-mediated mRNA decay. The mutations
depicted below the polypeptide are glycine substitution mutations within the collagenous domain. The majority of these missense mutations cause dom-
inantly inherited dystrophic EB through dominant negative interference. (Modi¢ed from Pulkkinen and Uitto, 1999.)
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large deletions in the ABCC6 gene (Fig 2). The majority of the
mutations reside in the carboxyl-terminal half of the MRP6
polypeptide, a¡ecting critical arginine residues or other con-
served amino acids. Furthermore, premature termination codon
mutations or large deletions frequently lead to elimination of
the third transmembrane domain and the second nucleotide-
binding fold. Finally, gene conversion between ABCC6 and one
of its pseudogenes has been suggested as a pathogenetic event in
some families with PXE (Cai et al, 2001). The mutations in
ABCC6 are present either in a homozygous or in a compound
heterozygous state in the a¡ected individuals, whereas heterozy-
gous carriers are clinically una¡ected, consistent with autosomal
recessive inheritance pattern. In fact, no molecular evidence for
autosomal dominant mode of inheritance has been demonstrated
as yet, although some of the heterozygous carriers may demonstrate
minimal manifestations of the disease (Sherer et al, 2001). Also,
in some families, the proposed autosomal dominant mode
of inheritance could be explained by a pseudodominant family
pedigree due to consanguinity in the family (Ringpfeil et al,
2000).
A surprising ¢nding in the context of clinical manifestations
of PXE is the fact that ABCC6/MRP6 is expressed predomi-
nantly, if not exclusively, in the liver and the kidneys. The biolo-
gical function of MRP6 is currently unknown, but there is
strong sequence homology with other members of the MRP fa-
mily, particularly with MRP1, the prototypic protein within the
family, which functions as an e¥ux pump for amphipathic and
glutathione conjugates. These observations suggest that MRP6 is
a metabolic pump expressed in the liver and the kidneys, and
PXE could potentially be considered as a metabolic disorder,
rather than being a primary connective tissue disease (Uitto et al,
2001). One could speculate that when MRP6 as a cellular trans-
porter is genetically altered to be nonfunctional, accumulation of
yet to be identi¢ed compounds in the circulation could take
place. Such compounds could have a⁄nity for elastic ¢bers and
calcium and potentially lead to progressive calci¢cation of elastic
structures in the a¡ected organs, resulting in progressive degen-
eration and pathology in the target tissues.
THE IMPACT OF MOLECULARGENETICS ON PATIENT
CARE
The progress made in understanding EB, PXE, and other geno-
dermatoses raises a number of critical questions: What are the
bene¢ts of this progress in basic research to the patients and
their families? How can we translate this basic information to
improved patient care? Is there anything that the practicing
Figure 2. Schematic representation of MRP6, a putative transporter protein, altered by mutations in PXE. As shown, MRP6 consists of three
transmembrane domains with ¢ve, six, and six transmembrane spanning segments, respectively.The protein is predicted to have two intracellular nucleotide
binding folds (NBF1 and NBF2). The repertoire of mutations within MRP6, as recently published (Cai et al, 2001; Le Saux et al, 2001; Meloni et al, 2001;
Ringpfeil et al, 2001; Pulkkinen et al, 2001) is illustrated by arrows pointing to the regions a¡ected by mutations. The majority of the mutations replace
critical amino acid residues within the intracellular domains of MRP6 or cause premature termination of translation. Note the presence of large deletion
mutations depicted on the top of the ¢gure. Two recurrent mutations, R1141X and del exons 23^29, are in bold. EC, extracellular; IC, intracellular.
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dermatologist can convey to the bene¢t of the patients concern-
ing their disease and its molecular basis? In other words, what is
the impact of molecular genetics on the patient care? Collectively,
signi¢cant bene¢ts are already accruing from the basic research
on heritable blistering skin diseases, and expansion of the re-
search database will provide additional insights into the clinical
perspective of these conditions.
For example, the immediate bene¢ts for EB have already ma-
terialized through improved, molecularly based diagnosis with
re¢ned classi¢cation, which allows better prognostication regard-
ing the severity and the natural progress of the disease. An exam-
ple is provided by the junctional form of EB (JEB), which has
been traditionally divided, on the basis of the clinical outcome,
to two broad categories: (i) the Herlitz variant of JEB that is
usually lethal during the ¢rst few months of life; and (ii) the
non-Herlitz variant that demonstrates persistent blistering ten-
dency throughout the life, without signi¢cantly compromising
the overall lifespan. Molecular analysis of the JEB patients’ DNA
has revealed that those with the Herlitz variant harbor, as a gen-
eral rule, a premature termination codon mutation, i.e., a gene
defect that predicts synthesis of a truncated and nonfunctional
polypeptide, in both alleles of any of the three genes encoding
laminin 5 subunits (LAMA3, LAMB3, and LAMC2) (Nakano
et al, 2000). In contrast, patients with the non-Herlitz variants
harbor frequently a missense mutation, i.e., an amino acid substi-
tution-causing mutation, in one or both alleles of the corre-
sponding genes. Thus, analysis of DNA from a newborn with
clinical, histopathologic, and ultrastructural evidence of JEB al-
lows general predictions as to whether the disease is the severe
Herlitz (lethal) variant, or whether the individual is expected to
have relatively mild non-Herlitz JEB with a normal lifespan (Na-
kano et al, 2001a).
Another example of the impact of molecular genetics relates
to genetic counseling of families at risk for recurrence of the
disease in the same and subsequent generations. An example
is provided by a ‘‘sporadic’’ patient with relatively mild DEB
with no family history of the disease, and speci¢cally, both
parents being clinically normal. The disease in the a¡ected
individual could result either from a new (de novo) dominant
mutation in one allele of the type VII collagen gene, or the
disease could be a mild (mitis) recessive DEB due to mutations
in both type VII collagen alleles, inherited separately from
each parent. These two possibilities are indistinguishable by
clinical examination, as well as by histopathologic, immuno-
histochemical, and ultrastructural analysis (Hashimoto et al,
1999). This diagnostic dilemma can be solved, however, by analy-
sis of mutations in the DNA from the a¡ected individual and his/
her parents. Speci¢cally, presence of a single mutation in the
proband, in the absence of the corresponding mutation in
the parents’ DNA isolated from peripheral blood, indicates a
de novo dominant mutation. In contrast, identi¢cation of two
mutant alleles in the proband’s DNA and demonstration of their
presence in the respective parents signi¢es mitis recessive DEB.
The implications are, of course, that the risk of an a¡ected indivi-
dual in the case of de novo dominant DEB of having an a¡ected
child is one in two, or 50%, whereas the risk of the individual
with recessive DEB having an a¡ected o¡spring is very low, re-
£ecting the relatively low carrier frequency of EB (Pfendner et al,
2001). At the same time, the risk for the parents of the patient
with a de novo dominant mutation of having another a¡ected
child is relatively low, whereas the risk for the parents of the pa-
tient with a recessive DEB having another a¡ected o¡spring is
one in four, or 25%.
PRENATALTESTING, PREIMPLANTATION GENETIC
DIAGNOSIS, AND GENE THERAPY
A consequence of the identi¢cation of speci¢c mutations in gen-
odermatoses has been the development of DNA-based prenatal
testing for families at risk for recurrence of severe forms of the
disease. Such testing can be performed from a chorionic villus
sample as early as the tenth week of gestation or from early am-
niocentesis performed at the twelfth week. In fact, prenatal test-
ing has already been established for EB and is readily available for
the severe forms of recessive DEB and for the Herlitz type of JEB
during the ¢rst trimester of pregnancy (Christiano et al, 1996,
1997). Prenatal predictions have also been made in cases with EB
with pyloric atresia, a frequently lethal variant of EB (Nakano
et al, 2001b). DNA-based analysis has essentially replaced the pre-
viously employed fetal skin biopsy, which is performed late dur-
ing the second trimester, as a prenatal diagnostic tool for EB.
An extension of DNA-based prenatal testing is the develop-
ment of preimplantation genetic diagnosis (PGD), which is per-
formed in conjunction with in vitro fertilization (McGrath and
Handyside, 1998). In this procedure, the fertilized embryos are al-
lowed to grow in vitro to the eight-cell stage level, at which time
one cell is removed for mutation analysis. Subsequently, embryos
lacking the mutation are implanted into the uterus to establish
pregnancy, as routinely done as part of in vitro fertilization proto-
col, therefore excluding the recurrence of the disease in the fa-
mily. Thus, couples with a child previously a¡ected with EB, or
any other severe genodermatosis in which the molecular basis is
known, can now initiate the next pregnancy by knowing that
there are ways to ¢nd out the genotype of the fetus at the early
stages of pregnancy through DNA-based prenatal testing or even
before the pregnancy is established by applying PGD.
Finally, it is evident that identi¢cation of the underlying mo-
lecular defects in genodermatoses is a prerequisite for develop-
ment of successful therapies in the future. In particular,
development of gene therapy approaches requires precise knowl-
edge of the mutations in the a¡ected genes and their conse-
quences at the mRNA and protein levels (Uitto and Pulkkinen,
2000). Although successful application of gene therapy for treat-
ment of EB may still be several years away, rapid development of
new technologies or promising breakthroughs could lead to
durable gene therapy for these devastating skin diseases in
the future.
FUTURE PROSPECTS: COMPLEX DISORDERS AND
GENETIC SUSCEPTIBILITY
As illustrated above, signi¢cant progress has been made towards
understanding the molecular basis of a large number of genoder-
matoses, and in fact, the majority of the single gene disorders
may have been mapped to distinct genetic loci and the underly-
ing mutated genes have been identi¢ed. Nevertheless, the mole-
cular basis of a number of Mendelian disorders still awaits
clari¢cation, and it is becoming increasingly evident that a num-
ber of disorders can be caused by defects in di¡erent genes with
resulting phenocopies or closely resembling phenotypes (Table I).
An example of such molecular diversity isVohwinkel’s syndrome,
characterized by mutilating keratoderma with pseudoainhum,
ichthyosiform erythroderma, and deafness. Our original attempts
to clarify the genetic basis of Vohwinkel’s syndrome in a family
with keratoderma and erythroderma resulted in identi¢cation of
mutations in the gene encoding loricrin, a corni¢ed envelope
protein expressed in the epidermis (Maestrini et al, 1996). Subse-
quently, however, examination of families with classic, more
complete forms of Vohwinkel’s disease manifesting with deafness,
led to identi¢cation of mutations in the GJB2 gene encoding
connexin 26, a cell^cell communication protein (Maestrini et al,
1999). As another example, di¡erent variants of X-linked anhi-
drotic ectodermal dysplasia have been shown to result from mu-
tations, in addition to ED1, in the IKBKG gene that encodes
NEMO, a subunit of the IkB kinase complex (Table I). At the
same time, incontinentia pigmenti, a complex X-linked domi-
nant disorder, is also due to mutations in the IKBKG gene (Berlin
et al, 2002). The dramatic phenotypic di¡erences in X-linked ec-
todermal dysplasias, either with immunode¢ciency (EDA-ID) or
together with osteopetrosis and lymphedema (OL-EDA-ID), and
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in incontinentia pigmenti can be explained by the consequences
of the mutations within the same gene. Speci¢cally, loss of func-
tion mutations in IKBKG, which abolish NFkB signaling, result
in incontinentia pigmenti (Smahi et al, 2000). In contrast, muta-
tions which impair but do not abolish the NFkB signaling are
associated with EDAvariants with immune de¢ciency (Do⁄nger
et al, 2001). Furthermore, EDA variants without immune de¢-
ciency, can be caused by mutations in two di¡erent genes. The
X-linked variants are due to mutations in the ED1 gene encoding
ectodysplacin A, whereas the autosomal variants with essentially
identical phenotypes are due to mutations in the ectodysplacin A
receptor gene (DL) (Kere et al, 1996; Monreal et al, 1999). Both of
these gene products participate in NFkB signaling. Thus, further
expansion of the molecular basis of single gene disorders, with
extended mutation databases towards re¢nement of genotype/
phenotype correlations, is still required for understanding of a
number of single gene disorders.
At the same time, the molecular diagnostics of genodermatoses
is expanding to include complex genetic disorders towards iden-
ti¢cation of susceptibility genes (Table III). A prime example of
such conditions is psoriasis, which is clearly known to have a ge-
netic contribution with a major susceptibility locus residing on
chromosome 6 in association with the HLA locus. In fact, a num-
ber of candidate genes have been recently identi¢ed, and evidence
in support of certain genes or in favor of exclusion of the corre-
sponding genes is rapidly appearing in the literature (see, for ex-
ample, Mallon et al, 1999; Chia et al, 2000; O’Brien et al, 2001;
Asumalahti et al, 2002). Further examples of such conditions are
autoimmune disorders, such as systemic lupus erythematosus and
vitiligo, for which a shared genetic susceptibility locus has been
recently linked to chromosome 17p13 (Nath et al, 2001).
Another example of a relatively common, complex disorder is
atopic dermatitis, and the loci in£uencing atopy have been loca-
lized to a number of chromosomal regions, including chromo-
some 5q31. This region includes SPINK5, which has recently
been identi¢ed to cause Netherton syndrome, a rare recessive skin
disorder in which atopy is a universal component (Chavanas et al,
2000; Sprecher et al, 2001c). SPINK5 encodes a complex serine
protease inhibitor (LEKTI), which is expressed in epithelial and
mucosal surfaces as well as in the thymus. A number of coding
polymorphisms in the SPINK5 gene have been demonstrated,
and it was discovered that Glu420Lys shows signi¢cant associa-
tion with atopic dermatitis in two independent panels of families
(Walley et al, 2001). These results implicate a previously unrecog-
nized pathway for the manifestations of atopic dermatitis, and
they potentially provide means to interfere with the development
of this condition by pharmacologic means. Collectively, these de-
velopments herald the extension of molecular genetics to more
common cutaneous disorders for which the molecular basis and
the pathomechanisms will be the subject of intense research over
the next decade.
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